Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 3/20 | 0.40 |
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514716 | 0.93 | CHEK1 (0.70) | CHEK1KCNH2SYKKDRAURKA | |
| SCHEMBL6525536 | 0.90 | CHEK1 (0.66) | CHEK1KCNH2SYKTERT | |
| SCHEMBL6510579 | 0.83 | CHEK1 (0.80) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6512695 | 0.82 | CHEK1 (0.78) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6514689 | 0.82 | CHEK1 (0.62) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6508884 | 0.81 | CHEK1 (0.77) | CHEK1KCNH2SYKKDRAURKA | |
| SCHEMBL6517619 | 0.81 | CHEK1 (0.77) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6518189 | 0.81 | CHEK1 (0.77) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6515391 | 0.81 | CHEK1 (0.77) | CHEK1KCNH2KDRAURKAAURKB | |
| SCHEMBL6517703 | 0.81 | CHEK1 (1.00) | CHEK1KCNH2KDRAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885KCNH2 3052/4885SYK 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.